Abnormalities of carnitine metabolism in chronic fatigue syndrome.
Majeed, T, de Simone, C, Famularo, G et al. · European journal of neurology · 1995 · DOI
Quick Summary
This study examined carnitine, a substance that helps cells produce energy, in people with ME/CFS. Researchers found that while carnitine levels in the blood were normal, the levels inside immune cells were significantly lower in ME/CFS patients compared to healthy people. This finding suggests that ME/CFS patients might benefit from taking carnitine supplements to restore normal energy production.
Why It Matters
This study provides early evidence of an energy metabolism defect specific to the cellular level in ME/CFS, which could explain the hallmark post-exertional symptom worsening. If carnitine deficiency is a consistent finding across tissues, it could lead to targeted supplementation strategies as a potential therapeutic intervention for ME/CFS.
Observed Findings
Serum carnitine levels (total, free, and short-chain) were comparable between ME/CFS patients and healthy controls
A non-significant trend toward reduced serum free carnitine was observed in male ME/CFS patients
Peripheral blood lymphocyte carnitine concentrations (total, free, and short-chain) were significantly lower in ME/CFS patients than controls
Cellular carnitine deficiency in PBLs suggests potential deficiency in other tissues including skeletal muscle
Inferred Conclusions
ME/CFS patients have a cellular carnitine deficiency that may not be reflected in circulating serum levels
Carnitine deficiency in cells may contribute to both immunological abnormalities and impaired muscle energy metabolism in ME/CFS
ME/CFS patients may require exogenous carnitine supplementation to restore normal cellular energy production
Remaining Questions
Is carnitine deficiency present in skeletal muscle and other tissues directly, or only in immune cells?
Does carnitine supplementation improve symptoms or objective measures of ME/CFS severity?
Is the carnitine deficiency primary (a causative factor) or secondary (a consequence of the disease process)?
What This Study Does Not Prove
This study does not establish whether carnitine deficiency is a cause or a consequence of ME/CFS. It also does not prove that carnitine supplementation will be effective or beneficial in ME/CFS patients, nor does it determine whether deficiency occurs in skeletal muscle or other tissues directly (only inferred from PBL findings). The small sample size and cross-sectional design limit causal inference.